Key Facts
| Founded: | September 2002 |
| Location: | Shanghai, China |
| Core activities: | Discovery and development of innovative human therapeutics |
| Therapeutic focus: | Cancer and autoimmune diseases |
| Geographic focus: | Worldwide |
| Founder & Chief Executive Officer: | Dr. Samantha Du |
| Number of employees: | More than 220 employees 30%+ MD/PhDs 50%+ Masters degrees |
| Facilities: | Two state-of-the-art R&D facilities Total area of 75,000 ft2 (7,000 m2) |
| Key shareholder: | Hutchison China MediTech Limited (AIM:HCM) |
| Major products in development: | HMPL-004 for Inflammatory Bowel Disease HMPL-011 for Inflammation HMPL-012 for cancer HMPL-013 for cancer HMPL-813 for cancer HMPL-309 for cancer |
| Corporate partners: | Eli Lilly Johnson & Johnson Merck Serono Proctor & Gamble |
| Institute and hospital partners: | Cambridge University University of Maryland Cedars-Sinai Medical Center Mayo Clinic University of California, Los Angeles Shanghai Institute of Materia Medica Shanghai Institute of Pharmaceutical Industry National Shanghai Center for New Drug Safety Evaluation and Research Institute for Nutritional Sciences Shanghai University of TCM Peking University School of Pharmaceutical Sciences Shenyang Pharmaceutical University Chinese PLA General Hospital Cancer Institute and Hospital, Chinese Academy of Medical Sciences Beijing Cancer Hospital Zhongshan Hospital Fudan University Shanghai Chest Hospital Changhai Hospital of Shanghai |
| Awards & recognition: | 2009 Scrip Awards — Shortlist for Best Company in Emerging Markets 2009 Innovation Forum — China’s Most Innovative Enterprise 2009 Global Entrepreneur — The Best Chinese R&D Team 2008 In Vivo — Genentech from China 2008 Red Herring — Asia 100 Winners 2007 Scrip Awards — Best Company in Emerging Market 2007 Forbes — Ancient Secrets 2006 Forbes — Pioneer in China R&D |
| Drug Discovery capabilities: | New chemical entity expertise in biology, chemistry, pharmacology, Drug Metabolism & Pharmacokinetics (DMPK), and drug safety evaluation |
| Drug Development capabilities: | Expertise in chemistry, manufacturing & control (CMC), clinical development, and regulatory affairs |
| Contact information: | Tel: +86 21 5079 0088 Fax: +86 21 5079 3900 Email: BD@hmplglobal.com |
